Bruker (BRKR) Gets a Buy from Bank of America Securities
In a report released today, Michael Ryskin from Bank of America Securities maintained a Buy rating on Bruker (BRKR – Research Report). The ...
Bruker projects 11%-13% EPS growth and 140 bps margin expansion for 2025 amid strong semi and diagnostics performance
Discover key takeaways from Bruker Corporation's Q4 2024 earnings call, highlighting strong diagnostics, semiconductor growth, and confident 2025 ...
Le Lézard2d
Glenmark Pharmaceuticals Inc., USA launches Clindamycin Phosphate Foam, 1%
Glenmark Pharmaceuticals Inc., USA (Glenmark) announces the launch1 of Clindamycin Phosphate Foam, 1%. Glenmark's Clindamycin Phosphate Foam, 1% is bioequivalent and therapeutically equivalent to the ...
Canada3d
Scientific Research and Experimental Development (SR&ED) tax incentives
The Scientific Research and Experimental Development (SR&ED) tax incentives are intended to encourage businesses to conduct research and development in Canada. Corporations, individuals, trusts, and ...
Bruker price target lowered to $65 from $69 at Barclays
Barclays analyst Luke Sergott lowered the firm’s price target on Bruker to $65 from $69 and keeps an Overweight rating on the shares. The firm ...